Human Papillomavirus (HPV) Testing Updates

Human papillomavirus (HPV) is the most common sexually transmitted viral infection in the United States.

Most HPV infections are benign and resolve on their own, but persistent infection with any of the high-risk HPV genotypes increases a woman’s risk for developing cervical cancer. 

To assist in the detection and surveillance of HPV infections, ARUP offers multiple molecular screening and testing options based on current cervical cancer screening guidelines from the American College of Obstetricians and Gynecologists (ACOG), the American Society for Colposcopy and Cervical Pathology (ASCCP), the United States Preventive Services Task Force (USPSTF), and the American Cancer Society (ACS).  

Upcoming Changes to HPV Screening Testing

Test Name Test Number Test Utility Result Type HPV Genotypes Tested and Reported Important Dates
Human Papillomavirus (HPV) High Risk Screen by Transcription-Mediated Amplification (TMA), with Reflex to Genotypes 16 and 18/45, ThinPrep 3016945

HPV screen with reflex to genotyping

This assay is a screening method with additional genotype differentiation

Detected/Not Detected

Detected reported with genotype differentiation

16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

If detected, high-risk genotypes HPV 16 and HPV 18/45 will be reported

Available now
Human Papillomavirus (HPV) High Risk Screen, by Transcription-Mediated Amplification (TMA), ThinPrep 3016943

HPV screen only

This assay is the preferred screening method for HPV

Detected/Not Detected

16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

If high-risk genotypes are present, reported as “detected”


Genotypes not differentiated

Available now
Human Papillomavirus (HPV) Genotypes 16 and 18/45, by Transcription-Mediated Amplification (TMA), ThinPrep 3016944 Genotyping only Genotype differentiation

16 and 18/45

If detected, high-risk genotypes HPV 16 and HPV 18/45 will be reported

Available now
Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by Nucleic Acid Amplification (NAA), ThinPrep 3003005 Screen with simultaneous genotyping

Detected/Not Detected

Detected reported with genotype differentiation

16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

If detected, high-risk genotypes HPV 16, HPV 18/45, and other high-risk HPV will be reported

Inactive Feb. 2024, for an alternative, see 3016945
HPV Primary Screen by PCR w/ Reflex to Cytology. 
 
3016636 Screen with reflex to cytology

Detected/Not Detected

Detected reported with genotype differentiation

Cytology by report

16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

If detected, high-risk genotypes HPV 16 and HPV 18 will be differentiated, and specimen will be reflexed to cytology 

Coming soon! Available Feb. 2024

 


Why Choose ARUP?

solutions-workflow

Flexible Testing Options

Clinicians have the ability to order the testing indicated for individual patient populations.

finance-lower

Cost Saving Opportunities

ARUP offers multiple HPV testing options at various price points.

badge-guarantee

Reliable Results

ARUP’s screening tests detect 14 high-risk HPV genotypes in a single analysis, differentiates HPV16 and HPV18 from other high-risk types, and aligns reporting with current cervical cancer screening guidelines.

Additional Resources

Education

An Update on HPV Versus Non-HPV-Associated Endocervical Adenocarcinoma 
Video Lecture by Lesley C. Lomo, MD
Pathologist